Immune boosting duo takes on rare throat cancer
NCT ID NCT03097939
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests whether combining two immunotherapy drugs, ipilimumab and nivolumab, can shrink tumors in people with advanced nasopharyngeal carcinoma (NPC) linked to the Epstein-Barr virus. About 113 patients with recurrent or metastatic NPC that can't be cured will receive the drugs every few weeks. The main goal is to see how many patients have their tumors shrink or disappear.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ipilimumab (Yervoy) and Nivolumab (Opdivo)
What this could lead to
If successful, this combination could offer a new treatment option for advanced nasopharyngeal carcinoma, potentially shrinking tumors and delaying disease progression.
What could go wrong
This is a mid-stage trial with 113 participants, so results may not apply to everyone. The drugs can cause immune-related side effects, and not all patients may respond.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Center Singapore
Singapore, 169610, Singapore